| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$151.8M | ROE | −36.91% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Mineralys Therapeutics is a biopharmaceutical company developing medicines targeting diseases driven by dysregulated aldosterone in the United States. Its candidate lorundrostat is an orally administered, selective aldosterone synthase inhibitor for cardiorenal conditions including hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1 and is headquartered in Radnor, Pennsylvania.
| Market Cap | $2.22B | Trading Days | 840 |
| 52W High | 47.65 |
| 52W Low | 12.59 |
| % Off High | −43.44% |
| YTD | −25.74% | 1Y | 98.16% |
| 3Y | 85.48% | Since incept. (ann.) | 15.98% |
| Ann. Volatility (1Y) | 106.63% | Ann. Volatility (3Y) | 85.66% |
| Sharpe (1Y) | 1.06 | Sharpe (3Y) | 0.63 |
| Max Drawdown (1Y) | −52.46% | Max Drawdown (3Y) | −58.98% |
| Beta (3Y, vs SPY) | 0.70 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc. | $2.26B | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.17B | — |
| ALMS | ALUMIS INC. | $2.30B | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.14B | — |
| NUVB | Nuvation Bio Inc. | $2.33B | — |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |
| IMUX | IMMUNIC, INC. | $2.08B | — |
| BHVN | Biohaven Ltd. | $2.07B | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.07B | 13.2 |
| NKTR | NEKTAR THERAPEUTICS | $2.39B | — |
| VERA | Vera Therapeutics, Inc. | $2.39B |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.05B | — |
